Epitope Specific Proportions of Envelope Protein Specific IgM and IgG from DENV-2 Infected Human Sera.

1The mutant antigens used are all knock-out mutants. The symbols * and † depict significantly different mean endpoint titers determined with antigens sharing the same symbol. Mean endpoint titers were considered significantly different when the 95% confidence interval for the difference between the means did not cross zero.2Epitope specific antibody populations targeted by the different knock-out antigens. WT antigen measures antibody recognizing all E-protein epitopes. EDIIFP denotes broadly cross-reactive epitopes incorporating the E-protein structural domain II fusion peptide. EDIIICR denotes predominately complex cross-reactive epitopes incorporating residues within E-protein structural domain III. EDIIFP−EDIIICR denotes individual or overlapping epitopes incorporating either or both the EDII fusion peptide or EDIII. EDIIITS denotes EDIII DENV-2 type-specific epitopes and were determined by the reactivity difference between the K305E and K388D antigens (see methods for details).3Endpoint titers determined with the knock-out antigen, thus representing immunoglobulins recognizing epitopes not targeted by the knock-out antigen. Because the EDIII DENV-2 type-specific response was calculated as the percent difference between K305E and K388D reactivities, the titers for EDIIITS were calculated as the WT titers multiplied by the percent EDIIITS response.4Because the mutant antigens knock-out antibody recognition of specific epitopes, the percent of immunoglobulin recognizing a particular epitope was determined for each individual sera by calculating the percent reactivity measured with a mutant antigen relative to that determined with the WT antigen and subtracting this value from 1.0; (1- [Endpointmutant/Endpointwt])×100; for the percent DENV-2 specific reactivity we used (1-[(EndpointK305E/EndpointWT)−(EndpointK388D)/EndpointWT)])×100.